ASH 2011 - San Diego -  CML - Chronic Myeloid Leukemia


2011 ASH Annual Meeting and Exposition - December 10-13, 2011
 
CML Program 

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy

Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.

632. Chronic Myeloid Leukemia: Therapy

Includes diagnosis, prognosis, therapy, epidemiology, complications, follow-up, quality of life, and socioeconomic aspects. For comparative trials of treatment regimens versus transplantation, see category 731.

December 12, 2011 1:30 PM-2:30 PM
San Diego Convention Center (Hall AB)

"Chronic myeloid leukemia (CML) was virtually uniformly fatal before the late 1990s with a median survival of about three years. In 1960, a unique small marker chromosome called the Philadelphia (Ph1) chromosome was identified. In 1973, it was determined to be a translocation that led to a fusion of the involved genes on chromosomes 9 and 22; the gene on 9 was the Abelson (ABL) oncogene, a known tyrosine kinase. This knowledge led to the development of an inhibitor of the ABL tyrosine kinase that specifically killed cultured CML cells. Clinical trials confirmed these pre-clinical observations and this oral drug, imatinib (Gleevec or STI571), has revolutionized treatment with five-year survival rates of almost 90 percent. Thus, although it took 40 years, CML is a story of success, from the identification of a unique genetic change to the development of a remarkably effective genetically targeted therapy. Dr. Janet Rowley will discuss the discovery of the chromosome translocations and cloning of the translocation breakpoint. Dr. Brian Druker will discuss the pre-clinical and clinical development of ABL inhibitors, including the problem of resistance."

Chair(s):

Janet D. Rowley, MD                                Brian J. Druker, MD
Univ. of Chicago Med. Ctr.                        OHSU Knight Cancer Institute
Chicago, IL, USA                                       Portland, OR, USA

ASH NEWS DAILY – Ernest Beutler Lectures Work Toward CML Cure with Dr. Janet Rowley and Dr. Brian

                                                 Return to other ASH Annual Meetings